Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine.
BMJ Case Rep
; 15(5)2022 May 20.
Article
in English
| MEDLINE | ID: covidwho-1861598
ABSTRACT
mRNA vaccines including Pfizer BioNTech and Moderna have categorically been considered safe when it comes to preventing COVID-19. However, there is still a small associated risk of thromboembolic phenomenon including venous sinus thrombosis with it and our case report highlights one.We describe a patient who developed severe progressive headache, tinnitus and visual disturbance symptoms post-Pfizer-SARS-CoV-2 vaccination. His medical history included essential tremors, hypertension, type 2 diabetes mellitus, chronic kidney disease stage 3, anxiety, depression and long-term catheterisation. Systemic examination revealed hypotonia, generalised reduced power and central diplopia along with peripheral visual field defect in the left eye. He was extensively investigated, the COVID-19 PCR test was negative and all routine blood tests were in the normal range except a marginally raised D-dimer of 779 ng/mL. CT head was unremarkable. He was also tested for myasthenia gravis; however, acetylcholine receptors antibodies were negative and nerve conduction studies were normal. Subsequent MRI of the brain with venography confirmed venous sinus thrombosis. A 24-hour Holter monitoring test did not reveal any cardiac rate or rhythm abnormality. He was treated with apixaban as per a neurologist's advice. His clinical condition started to improve and was later discharged from the hospital with an outpatient neurologist clinic follow-up.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Sinus Thrombosis, Intracranial
/
Diabetes Mellitus, Type 2
/
COVID-19
/
BNT162 Vaccine
Type of study:
Case report
/
Cohort study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
/
Male
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Bcr-2021-247493
Similar
MEDLINE
...
LILACS
LIS